Trial Profile
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 29 Oct 2021 Status changed from suspended to discontinued.
- 23 Mar 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 23 Mar 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.